

Final Appraisal Recommendation

Advice No: 0120 – February 2020

Plerixafor (Mozobil®) 20 mg/ml solution for injection

Limited submission by Sanofi Aventis

Recommendation of AWMSG

Plerixafor (Mozobil®) is recommended for use within NHS Wales in combination with granulocyte colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children aged ≥ 1 to <18 years with lymphoma or solid malignant tumours either:

- **pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired haematopoietic stem cells yield, or**
- **who previously failed to collect sufficient haematopoietic stem cells.**

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- AWMSG considered plerixafor (Mozobil®) as an ultra-orphan medicine according to the criteria in the AWMSG appraisal process for a medicine for a rare disease.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3297), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0120:
Plerixafor (Mozobil®) 20 mg/ml solution for injection February 2020